Edi Brogi

List of Publications by Year
in descending order

119 papers	9,767 citations	70961 41 h-index	39575 94 g-index
121 all docs	121 docs citations	121 times ranked	14307 citing authors

#	Article	IF	Citations
1	Clinical-grade computational pathology using weakly supervised deep learning on whole slide images. Nature Medicine, 2019, 25, 1301-1309.	15.2	1,320
2	Serpins Promote Cancer Cell Survival and Vascular Co-Option in Brain Metastasis. Cell, 2014, 156, 1002-1016.	13.5	672
3	The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell, 2018, 34, 427-438.e6.	7.7	633
4	Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss. Genes and Development, 2016, 30, 34-51.	2.7	488
5	The 2019 World Health Organization classification of tumours of the breast. Histopathology, 2020, 77, 181-185.	1.6	395
6	Tumor Heterogeneity in Breast Cancer. Frontiers in Medicine, 2017, 4, 227.	1.2	379
7	Selection of Bone Metastasis Seeds by Mesenchymal Signals in the Primary Tumor Stroma. Cell, 2013, 154, 1060-1073.	13.5	359
8	Phyllodes tumours of the breast: a consensus review. Histopathology, 2016, 68, 5-21.	1.6	329
9	Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. Cancer Cell, 2018, 34, 893-905.e8.	7.7	307
10	Analysis of tumour- and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role forÂcathepsin S. Nature Cell Biology, 2014, 16, 876-888.	4.6	300
11	TGF-Î²-Id1 Signaling Opposes Twist1 and Promotes Metastatic Colonization via a Mesenchymal-to-Epithelial Transition. Cell Reports, 2013, 5, 1228-1242.	2.9	205
12	Multi-organ Site Metastatic Reactivation Mediated by Non-canonical Discoidin Domain Receptor 1 Signaling. Cell, 2016, 166, 47-62.	13.5	194
13	PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3KÎ± Inhibition. Cancer Cell, 2016, 30, 229-242.	7.7	187
14	Pericyte-like spreading by disseminated cancer cells activates YAP and MRTF for metastatic colonization. Nature Cell Biology, 2018, 20, 966-978.	4.6	186
15	The path to a better biomarker: application of a risk management framework for the implementation of PDâ€L1 and TILs as immunoâ€oncology biomarkers in breast cancer clinical trials and daily practice. Journal of Pathology, 2020, 250, 667-684.	2.1	142
16	Occult Axillary Node Metastases in Breast Cancer Are Prognostically Significant: Results in 368 Node-Negative Patients With 20-Year Follow-Up. Journal of Clinical Oncology, 2008, 26, 1803-1809.	0.8	140
17	The Genomic Landscape of Male Breast Cancers. Clinical Cancer Research, 2016, 22, 4045-4056.	3.2	119
18	Intracystic Papillary Carcinoma of the Breast. American Journal of Surgical Pathology, 2011, 35, 1-14.	2.1	118

#	Article	IF	Citations
19	Classic lobular carcinoma in situ and atypical lobular hyperplasia at percutaneous breast core biopsy. Cancer, 2013, 119, 1073-1079.	2.0	112
20	Validation of a digital pathology system including remote review during the COVID-19 pandemic. Modern Pathology, 2020, 33, 2115-2127.	2.9	112
21	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. Npj Breast Cancer, 2020, 6, 17.	2.3	106
22	Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas. Nature Communications, 2018, 9, 1816.	5.8	105
23	Desmoid Tumors (Fibromatoses) of the Breast: A 25-Year Experience. Annals of Surgical Oncology, 2008, 15, 274-280.	0.7	104
24	Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and <scp>TERT</scp> promoter hotspot mutations and TERT gene amplification as likely drivers of progression. Journal of Pathology, 2016, 238, 508-518.	2.1	102
25	The Results of Frozen Section, Touch Preparation, and Cytological Smear Are Comparable for Intraoperative Examination of Sentinel Lymph Nodes: A Study in 133 Breast Cancer Patients. Annals of Surgical Oncology, 2005, 12, 173-180.	0.7	101
26	IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity. Cancer Research, 2016, 76, 7118-7129.	0.4	99
27	Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology. Modern Pathology, 2016, 29, 476-488.	2.9	95
28	MED12 somatic mutations in fibroadenomas and phyllodes tumours of the breast. Histopathology, 2015, 67, 719-729.	1.6	78
29	Breast intraductal papillomas without atypia in radiologicâ€pathologic concordant coreâ€needle biopsies: Rate of upgrade to carcinoma at excision. Cancer, 2016, 122, 2819-2827.	2.0	78
30	Mesothelin Expression in Triple Negative Breast Carcinomas Correlates Significantly with Basal-Like Phenotype, Distant Metastases and Decreased Survival. PLoS ONE, 2014, 9, e114900.	1.1	77
31	Deep Multi-Magnification Networks for multi-class breast cancer image segmentation. Computerized Medical Imaging and Graphics, 2021, 88, 101866.	3.5	69
32	The Genomic Landscape of Mucinous Breast Cancer. Journal of the National Cancer Institute, 2019, 111, 737-741.	3.0	68
33	Endosalpingiosis in Axillary Lymph Nodes: A Possible Pitfall in the Staging of Patients With Breast Carcinoma. American Journal of Surgical Pathology, 2010, 34, 1211-1216.	2.1	66
34	A machine learning model that classifies breast cancer pathologic complete response on MRI post-neoadjuvant chemotherapy. Breast Cancer Research, 2020, 22, 57.	2.2	63
35	MaTAR25 lncRNA regulates the Tensin1 gene to impact breast cancer progression. Nature Communications, 2020, 11, 6438.	5.8	63
36	Lobular Carcinoma In Situ. Surgical Pathology Clinics, 2018, 11, 123-145.	0.7	58

#	Article	IF	Citations
37	Selecting Node-Positive Patients for Axillary Downstaging with Neoadjuvant Chemotherapy. Annals of Surgical Oncology, 2020, 27, 4515-4522.	0.7	55
38	Phyllodes tumors with and without fibroadenoma-like areas display distinct genomic features and may evolve through distinct pathways. Npj Breast Cancer, 2017, 3, 40.	2.3	52
39	Sentinel lymph nodes for breast carcinoma: an update on current practice. Histopathology, 2016, 68, 152-167.	1.6	48
40	Cadherinâ€“catenin complex dissociation in lobular neoplasia of the breast. Breast Cancer Research and Treatment, 2012, 132, 641-652.	1.1	47
41	Secretory carcinoma of the breast: clinicopathologic profile of 14 cases emphasising distant metastatic potential. Histopathology, 2019, 75, 213-224.	1.6	46
42	Flura-seq identifies organ-specific metabolic adaptations during early metastatic colonization. ELife, 2019, 8, .	2.8	46
43	Ductal lavage in patients undergoing mastectomy for mammary carcinoma. Cancer, 2003, 98, 2170-2176.	2.0	44
44	Solid papillary breast carcinomas resembling the tall cell variant of papillary thyroid neoplasms (solid papillary carcinomas with reverse polarity) harbour recurrent mutations affecting <scp>IDH</scp>2 and <scp>PIK</scp>3<scp>CA</scp>: a validation cohort. Histopathology, 2018, 73, 339-344.	1.6	44
45	Benign and malignant spindle cell lesions of the breast. Seminars in Diagnostic Pathology, 2004, 21, 57-64.	1.0	43
46	Biâ€allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer. Journal of Pathology, 2017, 242, 165-177.	2.1	43
47	Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy. Breast Cancer Research and Treatment, 2019, 177, 61-66.	1.1	42
48	Pleomorphic lobular carcinoma in situ of the breast: a single institution experience with clinical follow-up and centralized pathology review. Breast Cancer Research and Treatment, 2017, 165, 411-420.	1.1	38
49	Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma. Npj Breast Cancer, 2021, 7, 96.	2.3	38
50	Fine-needle aspiration cytology of mammary adenomyoepithelioma. Cancer, 2006, 108, 250-256.	2.0	36
51	Immunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: applications in the diagnosis of tall cell carcinoma with reverse polarity. Modern Pathology, 2020, 33, 1056-1064.	2.9	35
52	The Need to Examine Metastatic Tissue at the Time of Progression of Breast Cancer: Is Re-biopsy a Necessity or a Luxury?. Current Oncology Reports, 2011, 13, 17-25.	1.8	32
53	Gene expression profiling of lobular carcinoma in situ reveals candidate precursor genes for invasion. Molecular Oncology, 2015, 9, 772-782.	2.1	32
54	Impact of Margin Assessment Method on Positive Margin Rate and Total Volume Excised. Annals of Surgical Oncology, 2014, 21, 86-92.	0.7	31

#	Article	IF	Citations
55	Sentinel Lymph Nodes for Breast Carcinoma: A Paradigm Shift. Archives of Pathology and Laboratory Medicine, 2016, 140, 791-798.	1.2	31
56	21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer. Breast Cancer Research and Treatment, 2017, 166, 69-76.	1.1	31
57	Fibroepithelial Lesions in the Breast of Adolescent Females: A Clinicopathological Study of 54 Cases. Breast Journal, 2017, 23, 182-192.	0.4	31
58	Somatic mutations in leukocytes infiltrating primary breast cancers. Npj Breast Cancer, 2015, 1, 15005.	2.3	30
59	Aberrant E-cadherin staining patterns in invasive mammary carcinoma. World Journal of Surgical Oncology, 2005, 3, 73.	0.8	29
60	Carcinoid tumorlets simulate pulmonary metastases in women with breast cancer. Human Pathology, 2006, 37, 839-844.	1.1	28
61	Massively parallel sequencing analysis of synchronous fibroepithelial lesions supports the concept of progression from fibroadenoma to phyllodes tumor. Npj Breast Cancer, 2016, 2, 16035.	2.3	28
62	The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis. Breast Cancer Research and Treatment, 2017, 165, 65-76.	1.1	28
63	Does the Benefit of Sentinel Node Frozen Section Vary Between Patients With Invasive Duct, Invasive Lobular, and Favorable Histologic Subtypes of Breast Cancer?. Annals of Surgery, 2008, 247, 143-149.	2.1	27
64	The genomic landscape of metastatic histologic special types of invasive breast cancer. Npj Breast Cancer, 2020, 6, 53.	2.3	27
65	Myxoid fibroadenomas differ from conventional fibroadenomas: a hypothesisâ€generating study. Histopathology, 2017, 71, 626-634.	1.6	26
66	Spindle cell lesions of the breast: a diagnostic approach. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 127-145.	1.4	26
67	Lobular Carcinoma, Not Only a Classic. Breast Journal, 2010, 16, S10-S14.	0.4	25
68	Pleomorphic adenomas and mucoepidermoid carcinomas of the breast are underpinned by fusion genes. Npj Breast Cancer, 2020, 6, 20.	2.3	25
69	The clinical behavior and genomic features of the so-called adenoid cystic carcinomas of the solid variant with basaloid features. Modern Pathology, 2022, 35, 193-201.	2.9	25
70	Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma. Modern Pathology, 2020, 33, 2221-2232.	2.9	23
71	American Registry of Pathology Expert Opinions: The Spectrum of Lobular Carcinoma in Situ: Diagnostic Features and Clinical Implications. Annals of Diagnostic Pathology, 2020, 45, 151481.	0.6	23
72	Estimating the OncotypeDX score: validation of an inexpensive estimation tool. Breast Cancer Research and Treatment, 2017, 161, 435-441.	1.1	22

#	Article	IF	Citations
73	Benign vascular lesions of the breast diagnosed by core needle biopsy do not require excision. Histopathology, 2017, 71, 795-804.	1.6	22
74	Micropapillary variant of mucinous carcinoma of the breast shows genetic alterations intermediate between those of mucinous carcinoma and micropapillary carcinoma. Histopathology, 2019, 75, 139-145.	1.6	22
75	Recurrent MED12 exon 2 mutations in benign breast fibroepithelial lesions in adolescents and young adults. Journal of Clinical Pathology, 2019, 72, 258-262.	1.0	22
76	Assessment of HMGA2 and PLAG1 rearrangements in breast adenomyoepitheliomas. Npj Breast Cancer, 2019, 5, 6.	2.3	21
77	The genetic landscape of metaplastic breast cancers and uterine carcinosarcomas. Molecular Oncology, 2021, 15, 1024-1039.	2.1	21
78	Concurrent lobular neoplasia increases the risk of ipsilateral breast cancer recurrence in patients with ductal carcinoma in situ treated with breastâ€conserving therapy. Cancer, 2009, 115, 1203-1214.	2.0	19
79	Immunohistochemical assessment ofHRASQ61R mutations in breast adenomyoepitheliomas. Histopathology, 2020, 76, 865-874.	1.6	19
80	Accuracy of Magnetic Resonance Imagingâ€“Guided Biopsy to Verify Breast Cancer Pathologic Complete Response After Neoadjuvant Chemotherapy. JAMA Network Open, 2021, 4, e2034045.	2.8	19
81	Classification of benign endometrial glandular cells in cervical smears from postmenopausal women. Cancer, 2002, 96, 60-66.	2.0	18
82	Examination and prognostic implications of the unique microenvironment of breast cancer brain metastases. Breast Cancer Research and Treatment, 2019, 176, 321-328.	1.1	17
83	Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical followâ€up. Cancer, 2017, 123, 131-137.	2.0	16
84	TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer. Npj Breast Cancer, 2021, 7, 43.	2.3	16
85	The 21-Gene Recurrence Score in Male Breast Cancer. Annals of Surgical Oncology, 2018, 25, 1530-1535.	0.7	14
86	Papillary neoplasms of the breast including upgrade rates and management of intraductal papilloma without atypia diagnosed at core needle biopsy. Modern Pathology, 2021, 34, 78-93.	2.9	14
87	Automatic quantification of HER2 gene amplification in invasive breast cancer from chromogenic in situ hybridization whole slide images. Journal of Medical Imaging, 2019, 6, 1.	0.8	14
88	Is Sentinel Lymph Node Biopsy Required for a Core Biopsy Diagnosis of Ductal Carcinoma In Situ with Microinvasion?. Annals of Surgical Oncology, 2019, 26, 2738-2746.	0.7	13
89	Morphologic subtypes of lobular carcinoma in situ diagnosed on core needle biopsy: clinicopathologic features and findings at follow-up excision. Modern Pathology, 2021, 34, 1495-1506.	2.9	13
90	Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch Syndrome. Clinical Cancer Research, 2022, 28, 404-413.	3.2	13

#	Article	IF	Citations
91	Genetic analysis of uterine adenosarcomas and phyllodes tumors of the breast. Molecular Oncology, 2017, 11, 913-926.	2.1	11
92	Interobserver Variation of PD-L1 SP142 Immunohistochemistry Interpretation in Breast Carcinoma: A Study of 79 Cases Using Whole Slide Imaging. Archives of Pathology and Laboratory Medicine, 2021, 145, 1132-1137.	1.2	11
93	Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing. Modern Pathology, 2019, 32, 81-87.	2.9	10
94	Impact of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Updates on HER2 Assessment in Breast Cancer With Equivocal HER2 Immunohistochemistry Results With Focus on Cases With HER2/CEP17 Ratio <2.0 and Average HER2 Copy Number â‰¥4.0 and <6.0. Archives of Pathology and Laboratory Medicine, 2020, 144, 597-601.	1.2	10
95	Breast carcinoma with 21-gene recurrence score lower than 18: rate of locoregional recurrence in a large series with clinical follow-up. BMC Cancer, 2018, 18, 42.	1.1	9
96	Impact of biomarkers and genetic profiling on breast cancer prognostication: A comparative analysis of the 8th edition of breast cancer staging system. Breast Journal, 2019, 25, 829-837.	0.4	9
97	Multifocal/Multicentric Ipsilateral Invasive Breast Carcinomas with Similar Histology: Is Multigene Testing of All Individual Foci Necessary?. Annals of Surgical Oncology, 2019, 26, 329-335.	0.7	9
98	The impact of MYC gene amplification on the clinicopathological features and prognosis of radiationâ€associated angiosarcomas of the breast. Histopathology, 2021, 79, 836-846.	1.6	9
99	Androgen receptor splice variant-7 in breast cancer: clinical and pathologic correlations. Modern Pathology, 2022, 35, 396-402.	2.9	9
100	Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab. Npj Breast Cancer, 2022, 8, 37.	2.3	9
101	Digital validation of breast biomarkers (ER, PR, AR, and HER2) in cytology specimens using three different scanners. Modern Pathology, 2022, 35, 52-59.	2.9	8
102	Lobular Carcinoma in Situ, Classical Type and Unusual Variants. Surgical Pathology Clinics, 2009, 2, 273-299.	0.7	7
103	Wholeâ€exome analysis of metaplastic breast carcinomas with extensive osseous differentiation. Histopathology, 2020, 77, 321-326.	1.6	7
104	Nextâ€generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guideline. Histopathology, 2021, 78, 498-507.	1.6	7
105	HER2 Immunohistochemistry in Invasive Micropapillary Breast Carcinoma: Complete Assessment of an Incomplete Pattern. Archives of Pathology and Laboratory Medicine, 2021, 145, 979-987.	1.2	7
106	Triple-Positive Breast Carcinoma: Histopathologic Features and Response to Neoadjuvant Chemotherapy. Archives of Pathology and Laboratory Medicine, 2021, 145, 728-735.	1.2	7
107	Paired ductal lavage and fine-needle aspiration specimens from patients with breast carcinoma. Diagnostic Cytopathology, 2005, 33, 370-375.	0.5	6
108	The morphologic spectrum of lobular carcinoma in situ (LCIS) observations on clinical significance, management implications and diagnostic pitfalls of classic, florid and pleomorphic LCIS. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 481, 823-837.	1.4	6

#	Article	IF	Citations
109	Neuroendocrine tumours of the breast: a genomic comparison with mucinous breast cancers and neuroendocrine tumours of other anatomic sites. Journal of Clinical Pathology, 2020, , jclinpath-2020-207052.	1.0	5
110	Nonâ€invasive lobular neoplasia of the breast: Morphologic features, clinical presentation, and management dilemmas. Breast Journal, 2020, 26, 1148-1155.	0.4	5
111	<scp>Wholeâ€exome</scp> sequencing analysis of juvenile papillomatosis and coexisting breast carcinoma. Journal of Pathology: Clinical Research, 2021, 7, 113-120.	1.3	4
112	Morphologic and immunohistochemical features of carcinoma involving microglandular adenosis of the breast following neoadjuvant chemotherapy. Modern Pathology, 2021, 34, 1310-1319.	2.9	3
113	Histologic and genomic features of breast cancers with alterations affecting the SWI/SNF (SMARC) genes. Modern Pathology, 2021, 34, 1850-1859.	2.9	3
114	Expression Analysis of GD2 by Immunohistochemistry in Invasive Breast Carcinoma: Clinical and Pathologic Correlation. Applied Immunohistochemistry and Molecular Morphology, 2022, 30, 113-118.	0.6	3
115	Specimen Identification Errors in Breast Biopsies: Age Matters. Report of Two Near-Miss Events and Review of the Literature. Breast Journal, 2017, 23, 583-588.	0.4	2
116	Stromal MED12 exon 2 mutations in complex fibroadenomas of the breast. Journal of Clinical Pathology, 2022, 75, 133-136.	1.0	2
117	Quality Issues in Diagnostic Immunohistochemistry in Breast Pathology. Pathobiology, 2022, , 1-10.	1.9	2
118	Reply to â€œMulticentric Ipsilateral Invasive Breast Carcinomas Might Have Higher 21-Gene Recurrence Score Compared with Multifocal Ipsilateral Invasive Breast Carcinomasâ€• Annals of Surgical Oncology, 2019, 26, 310-311.	0.7	1
119	Breast Cancer Pathology. , 2019, , 87-127.		1